Atsena Therapeutics
Biotechnology · Clinical Trial Services (CRO)
$296Mtotal raised · 6 rounds on record
1open role
$150Mlatest round · Series C · Apr 2025 · 19 mo ago
2backers · Wellington Management, Lightstone Ventures
Overview
Atsena is a clinical-stage gene therapy company, focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
Funding and backers
Total raised
$296M
6 rounds on record
Latest round
$150M
Series C · Apr 2025 · 19 mo ago
Team
201-500
employees, estimated range
Hiring now
1
+1 posted in 30 days
Grants
$871k
1 grant · CORDIS
Backers
2
Wellington Management, Lightstone Ventures
The money's age
Due for its next round
19 months since the last round · and hiring
Momentum
28/100
hiring for its size, in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 19
Board appointment Atsena Therapeutics Appoints Matt Pauls to Board of Directors · atsenatx.com
Sep 15, 2025
Won a grant $871k · CORDIS
Apr 11, 2025
Board appointment Joe Zakrzewski, Director · SEC Form D
Apr 2, 2025
Raised a round Series C $150M
Oct 2, 2023
Board appointment Jacqueline Grant, Director · SEC Form D
Aug 28, 2023
Raised a round Venture round $24.5M · SEC Form D
Dec 15, 2020
Raised a round Venture round $27.5M · SEC Form D
Apr 24, 2020
Raised a round Venture round $4.1M · SEC Form D
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Sep 2025 | $871k | — | CORDIS |
| Series C | Apr 2025 | $150M | — | streetinsider.com |
| Venture round | Mar 2025 | $90M | — | SEC Form D |
| Venture round | Aug 2023 | $24.5M | — | SEC Form D |
| Venture round | Dec 2020 | $27.5M | — | SEC Form D |
| Venture round | Apr 2020 | $4.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Atsena Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Sanford BoyeExecutive OfficerSEC Form D
Shannon BoyeDirectorSEC Form D
Patrick RitschelExecutive Officer, DirectorSEC Form D
Elizabeth LeidermanExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Spur Therapeutics is a clinical-stage biotech that optimizes every component of its gene therapy candidates to change the course of…
GeneVentiv Therapeutics — advancing gene therapy approaches.
Instant Quantification of genetic modifications for Cell and Gene Therapies.
Carmine Therapeutics is pioneering a powerful new class of genetic medicines based on red blood cell extracellular vesicles (RBCEVs).
Code Biotherapeutics is an emerging next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to…
Innorna is a clinical-stage biotechnology company engineering mRNA-based medicines to treat chronic diseases, power in vivo…
Jobs
$160k – $220k per year · Remote (likely United States) · Full-Time · 10+ years exp
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$220k
Typical range
$220k
Open positions
1
1
Jobs
Architect
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Architect | 1 | $220k | $220k |
Highest paying role
Associate Director or Director, Regulatory Strategy (Clinical & Nonclinical)
$220k
Normalized to USD per year
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
100% ▲
Financials
Total raised
$296.9M
Latest round
Grant
Funding rounds
6
People
Sanford Boye
Executive Officer
Shannon Boye
Director
Patrick Ritschel
Executive Officer, Director
Elizabeth Leiderman
Executive Officer
Michael Dial
Director
Benjamin Yerxa
Director
Jennifer Wellman
Director
Jacqueline Grant
Director
James Healy
Director
Christina Isacson
Director
Chris Carpenter
Director
Norbert Riedel
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Lightstone VenturesVia a fund
Wellington ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Atsena Presents Positive Preliminary Safety and Efficacy Results from Parts A and B of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
ATSN-201 demonstrated structural and functional benefit in Parts A and B, including microperimetry improvements exceeding the level the FDA has defined as supportive of potential approval Atsena also reported new data demonstrating that three patients tre
Read more
Report
Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
18-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201's favorable safety profile and durable structural and functional benefits in patients with X-linked retinoschisis Pivotal Part C cohort enrollment expected to complete Q1 2027; topline re
Read more
Report
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
Matt Pauls brings more than 25 years of biopharma leadership and rare disease clinical development and commercial expertise as Atsena advances its...
Read more
Report
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
Matt Pauls brings more than 25 years of biopharma leadership and rare disease clinical development and commercial expertise as Atsena advances its ocular gene therapy pipeline toward commercialization DURHAM, NC - August 19, 2026 - Atsena Therapeutics, a
Read more
Report
Atsena Therapeutics Receives Orphan Designation from the European Medicines Agency (EMA) for ATSN-101 and ATSN-201
Orphan designation provides market exclusivity and development benefits in the European Union as both programs advance in global pivotal clinical trials DURHAM, NC, July 23, 2026 - Atsena Therapeutics, a clinical-stage gene therapy company focused on usin
Read more
Report
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
Proprietary dual-vector platform delivers full-length ABCA4, enabled by Atsena's laterally spreading AAV.SPR capsid for delivery to the central retina without foveal detachment ATSN-401 advancing in IND-enabling studies DURHAM, NC, July 9, 2026 - Atsena T
Read more
Report
Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
Enrollment expected to complete Q1 2027; topline results anticipated 1H 2028; BLA filing targeted for 2H 2028 Phase 1/2 data demonstrated ATSN-201's ability to reverse structural damage to the retina and improve vision in patients with XLRS DURHAM, NC, Ju
Read more
Report
Atsena Presents Positive Clinical Data from Its XLRS and LCA1 Gene Therapy Programs at ARVO 2026
12-month results from Part A of LIGHTHOUSE Trial reinforce ATSN-201's favorable safety profile and durable structural and functional benefits in patients with X-linked retinoschisis Three-year data from Phase 1/2 trial confirm durable efficacy and tolerab
Read more
Report
Atsena Presents Positive Interim Six-Month Results from Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
Six-month data from adult Cohort 4 show structural and functional improvements and a favorable safety profile; early safety data from pediatric Cohort 5 are consistent with adult cohorts Enrollment underway in pivotal Part C cohort; FDA is aligned with pr
Read more
Report
Atsena Therapeutics Announces Upcoming Presentations at Scientific and Medical Meetings
DURHAM, NC, April 23, 2026 - Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced upcoming presentations at the Foundation Fighting Blindne
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Durham
United States
HQ
200-500 est. staff